Influence of SGLT2 Inhibitors in Remodeling, Substrate and Ion Metabolism of Myocardium to Prevent Cardiovascular Risks: Recent Work and Advancement

Article ID: e171022210083 Pages: 12

  • * (Excluding Mailing and Handling)

Abstract

Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a new class of drugs that lower blood glucose levels while decreasing blood pressure, volume loss, and weight loss. SGLT2 inhibitors were studied to determine their effectiveness in treating cardiovascular disease and their side effects. Study outcomes related to cardiovascular and metabolic outcomes were examined in patients on SGLT2 inhibitors by searching PubMed, Embase, Cochrane, and SCOPUS. Articles related to clinical trials, reviews, and meta-analyses were considered. A review of SGLT2 inhibitors' mechanisms of action in preventing cardiovascular (CVS) disease progression was described. We then reviewed the possible effects of SGLT2 inhibitors on CVS dysfunction development, composition, and stability. In the following, we discussed the impact of SGLT2 inhibitors on CVD events, such as ischemic strokes and myocardial infarctions, and their role in treating congestive heart failure and cardiovascular mortality.

Graphical Abstract

[1]
Roth, G.A.; Mensah, G.A.; Johnson, C.O.; Addolorato, G.; Ammirati, E.; Baddour, L.M.; Barengo, N.C.; Beaton, A.Z.; Benjamin, E.J.; Benziger, C.P.; Bonny, A.; Brauer, M.; Brodmann, M.; Cahill, T.J.; Carapetis, J.; Catapano, A.L.; Chugh, S.S.; Cooper, L.T.; Coresh, J.; Criqui, M.; DeCleene, N.; Eagle, K.A.; Emmons-Bell, S.; Feigin, V.L.; Fernández-Solà, J.; Fowkes, G.; Gakidou, E.; Grundy, S.M.; He, F.J.; Howard, G.; Hu, F.; Inker, L.; Karthikeyan, G.; Kassebaum, N.; Koroshetz, W.; Lavie, C.; Lloyd-Jones, D.; Lu, H.S.; Mirijello, A.; Temesgen, A.M.; Mokdad, A.; Moran, A.E.; Muntner, P.; Narula, J.; Neal, B.; Ntsekhe, M.; Moraes de Oliveira, G.; Otto, C.; Owolabi, M.; Pratt, M.; Rajagopalan, S.; Reitsma, M.; Ribeiro, A.L.P.; Rigotti, N.; Rodgers, A.; Sable, C.; Shakil, S.; Sliwa-Hahnle, K.; Stark, B.; Sundström, J.; Timpel, P.; Tleyjeh, I.M.; Valgimigli, M.; Vos, T.; Whelton, P.K.; Yacoub, M.; Zuhlke, L.; Murray, C.; Fuster, V.; Roth, G.A.; Mensah, G.A.; Johnson, C.O.; Addolorato, G.; Ammirati, E.; Baddour, L.M.; Barengo, N.C.; Beaton, A.; Benjamin, E.J.; Benziger, C.P.; Bonny, A.; Brauer, M.; Brodmann, M.; Cahill, T.J.; Carapetis, J.R.; Catapano, A.L.; Chugh, S.; Cooper, L.T.; Coresh, J.; Criqui, M.H.; DeCleene, N.K.; Eagle, K.A.; Emmons-Bell, S.; Feigin, V.L.; Fernández-Sola, J.; Fowkes, F.G.R.; Gakidou, E.; Grundy, S.M.; He, F.J.; Howard, G.; Hu, F.; Inker, L.; Karthikeyan, G.; Kassebaum, N.J.; Koroshetz, W.J.; Lavie, C.; Lloyd-Jones, D.; Lu, H.S.; Mirijello, A.; Misganaw, A.T.; Mokdad, A.H.; Moran, A.E.; Muntner, P.; Narula, J.; Neal, B.; Ntsekhe, M.; Oliveira, G.M.M.; Otto, C.M.; Owolabi, M.O.; Pratt, M.; Rajagopalan, S.; Reitsma, M.B.; Ribeiro, A.L.P.; Rigotti, N.A.; Rodgers, A.; Sable, C.A.; Shakil, S.S.; Sliwa, K.; Stark, B.A.; Sundström, J.; Timpel, P.; Tleyjeh, I.I.; Valgimigli, M.; Vos, T.; Whelton, P.K.; Yacoub, M.; Zuhlke, L.J.; Abbasi-Kangevari, M.; Abdi, A.; Abedi, A.; Aboyans, V.; Abrha, W.A.; Abu-Gharbieh, E.; Abushouk, A.I.; Acharya, D.; Adair, T.; Adebayo, O.M.; Ademi, Z.; Advani, S.M.; Afshari, K.; Afshin, A.; Agarwal, G.; Agasthi, P.; Ahmad, S.; Ahmadi, S.; Ahmed, M.B.; Aji, B.; Akalu, Y.; Akande-Sholabi, W.; Aklilu, A.; Akunna, C.J.; Alahdab, F.; Al-Eyadhy, A.; Alhabib, K.F.; Alif, S.M.; Alipour, V.; Aljunid, S.M.; Alla, F.; Almasi-Hashiani, A.; Almustanyir, S.; Al-Raddadi, R.M.; Amegah, A.K.; Amini, S.; Aminorroaya, A.; Amu, H.; Amugsi, D.A.; Ancuceanu, R.; Anderlini, D.; Andrei, T.; Andrei, C.L.; Ansari-Moghaddam, A.; Anteneh, Z.A.; Antonazzo, I.C.; Antony, B.; Anwer, R.; Appiah, L.T.; Arabloo, J.; Ärnlöv, J.; Artanti, K.D.; Ataro, Z.; Ausloos, M.; Avila-Burgos, L.; Awan, A.T.; Awoke, M.A.; Ayele, H.T.; Ayza, M.A.; Azari, S. B, D.B.; Baheiraei, N.; Baig, A.A.; Bakhtiari, A.; Banach, M.; Banik, P.C.; Baptista, E.A.; Barboza, M.A.; Barua, L.; Basu, S.; Bedi, N.; Béjot, Y.; Bennett, D.A.; Bensenor, I.M.; Berman, A.E.; Bezabih, Y.M.; Bhagavathula, A.S.; Bhaskar, S.; Bhattacharyya, K.; Bijani, A.; Bikbov, B.; Birhanu, M.M.; Boloor, A.; Brant, L.C.; Brenner, H.; Briko, N.I.; Butt, Z.A.; Caetano dos Santos, F.L.; Cahill, L.E.; Cahuana-Hurtado, L.; Cámera, L.A.; Campos-Nonato, I.R.; Cantu-Brito, C.; Car, J.; Carrero, J.J.; Carvalho, F.; Castañeda-Orjuela, C.A.; Catalá-López, F.; Cerin, E.; Charan, J.; Chattu, V.K.; Chen, S.; Chin, K.L.; Choi, J.Y.J.; Chu, D.T.; Chung, S.C.; Cirillo, M.; Coffey, S.; Conti, S.; Costa, V.M.; Cundiff, D.K.; Dadras, O.; Dagnew, B.; Dai, X.; Damasceno, A.A.M.; Dandona, L.; Dandona, R.; Davletov, K.; De la Cruz-Góngora, V.; De la Hoz, F.P.; De Neve, J.W.; Denova-Gutiérrez, E.; Derbew Molla, M.; Derseh, B.T.; Desai, R.; Deuschl, G.; Dharmaratne, S.D.; Dhimal, M.; Dhungana, R.R.; Dianatinasab, M.; Diaz, D.; Djalalinia, S.; Dokova, K.; Douiri, A.; Duncan, B.B.; Duraes, A.R.; Eagan, A.W.; Ebtehaj, S.; Eftekhari, A.; Eftekharzadeh, S.; Ekholuenetale, M.; El Nahas, N.; Elgendy, I.Y.; Elhadi, M.; El-Jaafary, S.I.; Esteghamati, S.; Etisso, A.E.; Eyawo, O.; Fadhil, I.; Faraon, E.J.A.; Faris, P.S.; Farwati, M.; Farzadfar, F.; Fernandes, E.; Fernandez Prendes, C.; Ferrara, P.; Filip, I.; Fischer, F.; Flood, D.; Fukumoto, T.; Gad, M.M.; Gaidhane, S.; Ganji, M.; Garg, J.; Gebre, A.K.; Gebregiorgis, B.G.; Gebregzabiher, K.Z.; Gebremeskel, G.G.; Getacher, L.; Obsa, A.G.; Ghajar, A.; Ghashghaee, A.; Ghith, N.; Giampaoli, S.; Gilani, S.A.; Gill, P.S.; Gillum, R.F.; Glushkova, E.V.; Gnedovskaya, E.V.; Golechha, M.; Gonfa, K.B.; Goudarzian, A.H.; Goulart, A.C.; Guadamuz, J.S.; Guha, A.; Guo, Y.; Gupta, R.; Hachinski, V.; Hafezi-Nejad, N.; Haile, T.G.; Hamadeh, R.R.; Hamidi, S.; Hankey, G.J.; Hargono, A.; Hartono, R.K.; Hashemian, M.; Hashi, A.; Hassan, S.; Hassen, H.Y.; Havmoeller, R.J.; Hay, S.I.; Hayat, K.; Heidari, G.; Herteliu, C.; Holla, R.; Hosseini, M.; Hosseinzadeh, M.; Hostiuc, M.; Hostiuc, S.; Househ, M.; Huang, J.; Humayun, A.; Iavicoli, I.; Ibeneme, C.U.; Ibitoye, S.E.; Ilesanmi, O.S.; Ilic, I.M.; Ilic, M.D.; Iqbal, U.; Irvani, S.S.N.; Islam, S.M.S.; Islam, R.M.; Iso, H.; Iwagami, M.; Jain, V.; Javaheri, T.; Jayapal, S.K.; Jayaram, S.; Jayawardena, R.; Jeemon, P.; Jha, R.P.; Jonas, J.B.; Jonnagaddala, J.; Joukar, F.; Jozwiak, J.J.; Jürisson, M.; Kabir, A.; Kahlon, T.; Kalani, R.; Kalhor, R.; Kamath, A.; Kamel, I.; Kandel, H.; Kandel, A.; Karch, A.; Kasa, A.S.; Katoto, P.D.M.C.; Kayode, G.A.; Khader, Y.S.; Khammarnia, M.; Khan, M.S.; Khan, M.N.; Khan, M.; Khan, E.A.; Khatab, K.; Kibria, G.M.A.; Kim, Y.J.; Kim, G.R.; Kimokoti, R.W.; Kisa, S.; Kisa, A.; Kivimäki, M.; Kolte, D.; Koolivand, A.; Korshunov, V.A.; Koulmane Laxminarayana, S.L.; Koyanagi, A.; Krishan, K.; Krishnamoorthy, V.; Kuate Defo, B.; Kucuk Bicer, B.; Kulkarni, V.; Kumar, G.A.; Kumar, N.; Kurmi, O.P.; Kusuma, D.; Kwan, G.F.; La Vecchia, C.; Lacey, B.; Lallukka, T.; Lan, Q.; Lasrado, S.; Lassi, Z.S.; Lauriola, P.; Lawrence, W.R.; Laxmaiah, A.; LeGrand, K.E.; Li, M-C.; Li, B.; Li, S.; Lim, S.S.; Lim, L.L.; Lin, H.; Lin, Z.; Lin, R.T.; Liu, X.; Lopez, A.D.; Lorkowski, S.; Lotufo, P.A.; Lugo, A.; M, N.K.; Madotto, F.; Mahmoudi, M.; Majeed, A.; Malekzadeh, R.; Malik, A.A.; Mamun, A.A.; Manafi, N.; Mansournia, M.A.; Mantovani, L.G.; Martini, S.; Mathur, M.R.; Mazzaglia, G.; Mehata, S.; Mehndiratta, M.M.; Meier, T.; Menezes, R.G.; Meretoja, A.; Mestrovic, T.; Miazgowski, B.; Miazgowski, T.; Michalek, I.M.; Miller, T.R.; Mirrakhimov, E.M.; Mirzaei, H.; Moazen, B.; Moghadaszadeh, M.; Mohammad, Y.; Mohammad, D.K.; Mohammed, S.; Mohammed, M.A.; Mokhayeri, Y.; Molokhia, M.; Montasir, A.A.; Moradi, G.; Moradzadeh, R.; Moraga, P.; Morawska, L.; Moreno Velásquez, I.; Morze, J.; Mubarik, S.; Muruet, W.; Musa, K.I.; Nagarajan, A.J.; Nalini, M.; Nangia, V.; Naqvi, A.A.; Narasimha Swamy, S.; Nascimento, B.R.; Nayak, V.C.; Nazari, J.; Nazarzadeh, M.; Negoi, R.I.; Neupane Kandel, S.; Nguyen, H.L.T.; Nixon, M.R.; Norrving, B.; Noubiap, J.J.; Nouthe, B.E.; Nowak, C.; Odukoya, O.O.; Ogbo, F.A.; Olagunju, A.T.; Orru, H.; Ortiz, A.; Ostroff, S.M.; Padubidri, J.R.; Palladino, R.; Pana, A.; Panda-Jonas, S.; Parekh, U.; Park, E-C.; Parvizi, M.; Pashazadeh Kan, F.; Patel, U.K.; Pathak, M.; Paudel, R.; Pepito, V.C.F.; Perianayagam, A.; Perico, N.; Pham, H.Q.; Pilgrim, T.; Piradov, M.A.; Pishgar, F.; Podder, V.; Polibin, R.V.; Pourshams, A.; Pribadi, D.R.A.; Rabiee, N.; Rabiee, M.; Radfar, A.; Rafiei, A.; Rahim, F.; Rahimi-Movaghar, V.; Ur Rahman, M.H.; Rahman, M.A.; Rahmani, A.M.; Rakovac, I.; Ram, P.; Ramalingam, S.; Rana, J.; Ranasinghe, P.; Rao, S.J.; Rathi, P.; Rawal, L.; Rawasia, W.F.; Rawassizadeh, R.; Remuzzi, G.; Renzaho, A.M.N.; Rezapour, A.; Riahi, S.M.; Roberts-Thomson, R.L.; Roever, L.; Rohloff, P.; Romoli, M.; Roshandel, G.; Rwegerera, G.M.; Saadatagah, S.; Saber-Ayad, M.M.; Sabour, S.; Sacco, S.; Sadeghi, M.; Saeedi Moghaddam, S.; Safari, S.; Sahebkar, A.; Salehi, S.; Salimzadeh, H.; Samaei, M.; Samy, A.M.; Santos, I.S.; Santric-Milicevic, M.M.; Sarrafzadegan, N.; Sarveazad, A.; Sathish, T.; Sawhney, M.; Saylan, M.; Schmidt, M.I.; Schutte, A.E.; Senthilkumaran, S.; Sepanlou, S.G.; Sha, F.; Shahabi, S.; Shahid, I.; Shaikh, M.A.; Shamali, M.; Shamsizadeh, M.; Shawon, M.S.R.; Sheikh, A.; Shigematsu, M.; Shin, M-J.; Shin, J.I.; Shiri, R.; Shiue, I.; Shuval, K.; Siabani, S.; Siddiqi, T.J.; Silva, D.A.S.; Singh, J.A.; Mtech, A.S.; Skryabin, V.Y.; Skryabina, A.A.; Soheili, A.; Spurlock, E.E.; Stockfelt, L.; Stortecky, S.; Stranges, S.; Suliankatchi Abdulkader, R.; Tadbiri, H.; Tadesse, E.G.; Tadesse, D.B.; Tajdini, M.; Tariqujjaman, M.; Teklehaimanot, B.F.; Temsah, M-H.; Tesema, A.K.; Thakur, B.; Thankappan, K.R.; Thapar, R.; Thrift, A.G.; Timalsina, B.; Tonelli, M.; Touvier, M.; Tovani-Palone, M.R.; Tripathi, A.; Tripathy, J.P.; Truelsen, T.C.; Tsegay, G.M.; Tsegaye, G.W.; Tsilimparis, N.; Tusa, B.S.; Tyrovolas, S.; Umapathi, K.K.; Unim, B.; Unnikrishnan, B.; Usman, M.S.; Vaduganathan, M.; Valdez, P.R.; Vasankari, T.J.; Velazquez, D.Z.; Venketasubramanian, N.; Vu, G.T.; Vujcic, I.S.; Waheed, Y.; Wang, Y.; Wang, F.; Wei, J.; Weintraub, R.G.; Weldemariam, A.H.; Westerman, R.; Winkler, A.S.; Wiysonge, C.S.; Wolfe, C.D.A.; Wubishet, B.L.; Xu, G.; Yadollahpour, A.; Yamagishi, K.; Yan, L.L.; Yandrapalli, S.; Yano, Y.; Yatsuya, H.; Yeheyis, T.Y.; Yeshaw, Y.; Yilgwan, C.S.; Yonemoto, N.; Yu, C.; Yusefzadeh, H.; Zachariah, G.; Zaman, S.B.; Zaman, M.S.; Zamanian, M.; Zand, R.; Zandifar, A.; Zarghi, A.; Zastrozhin, M.S.; Zastrozhina, A.; Zhang, Z-J.; Zhang, Y.; Zhang, W.; Zhong, C.; Zou, Z.; Zuniga, Y.M.H.; Murray, C.J.L.; Fuster, V. Global burden of cardiovascular diseases and risk factors, 1990-2019: Update from the GBD 2019 study. J. Am. Coll. Cardiol., 2020, 76(25), 2982-3021.
[http://dx.doi.org/10.1016/j.jacc.2020.11.010] [PMID: 33309175]
[2]
Joseph, P.; Leong, D.; McKee, M.; Anand, S.S.; Schwalm, J.D.; Teo, K.; Mente, A.; Yusuf, S. Reducing the global burden of cardiovascular disease, part 1. Circ. Res., 2017, 121(6), 677-694.
[http://dx.doi.org/10.1161/CIRCRESAHA.117.308903] [PMID: 28860318]
[3]
Kundu, J.; Kundu, S. Cardiovascular disease (CVD) and its associated risk factors among older adults in India: Evidence from LASI Wave 1. Clin. Epidemiol. Glob. Health, 2022, 13100937
[http://dx.doi.org/10.1016/j.cegh.2021.100937]
[4]
Liu, M.B. Cardiovascular diseases. Chin. Med. J. (Engl.), 2014, 127, 6-7.
[PMID: 23557570]
[5]
Martín-Timón, I.; Sevillano-Collantes, C.; Segura-Galindo, A.; Del Cañizo-Gómez, F.J. Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength? World J. Diabetes, 2014, 5(4), 444-470.
[PMID: 25126392]
[6]
Ormazabal, V.; Nair, S.; Elfeky, O.; Aguayo, C.; Salomon, C.; Zuñiga, F.A. Association between insulin resistance and the development of cardiovascular disease. Cardiovasc. Diabetol., 2018, 17(1), 122.
[http://dx.doi.org/10.1186/s12933-018-0762-4] [PMID: 30170598]
[7]
Einarson, T.R.; Acs, A.; Ludwig, C.; Panton, U.H. Prevalence of cardiovascular disease in type 2 diabetes: A systematic literature review of scientific evidence from across the world in 2007-2017. Cardiovasc. Diabetol., 2018, 17(1), 83.
[http://dx.doi.org/10.1186/s12933-018-0728-6] [PMID: 29884191]
[8]
Schwarz, P.E.H.; Timpel, P.; Harst, L.; Greaves, C.J.; Ali, M.K.; Lambert, J.; Weber, M.B.; Almedawar, M.M.; Morawietz, H. Blood sugar regulation for cardiovascular health promotion and disease prevention: JACC health promotion series. J. Am. Coll. Cardiol., 2018, 72(15), 1829-1844.
[PMID: 30286928]
[9]
Qaseem, A.; Wilt, T.J.; Kansagara, D.; Horwitch, C.; Barry, M.J.; Forciea, M.A.; Fitterman, N.; Balzer, K.; Boyd, C.; Humphrey, L.L.; Iorio, A.; Lin, J.; Maroto, M.; McLean, R.; Mustafa, R.; Tufte, J. Haemoglobin A1c targets for glycemic control with pharmacologic therapy for nonpregnant adults with type 2 diabetes mellitus: A guidance statement update from the american college of physicians. Ann. Intern. Med., 2018, 168(8), 569-576.
[PMID: 29507945]
[10]
Chaudhury, A.; Duvoor, C.; Reddy Dendi, V.S.; Kraleti, S.; Chada, A.; Ravilla, R.; Marco, A.; Shekhawat, N.S.; Montales, M.T.; Kuriakose, K.; Sasapu, A.; Beebe, A.; Patil, N.; Musham, C.K.; Lohani, G.P.; Mirza, W. Clinical review of antidiabetic drugs: Implications for type 2 diabetes mellitus management. Front. Endocrinol., 2017, 8, 6.
[http://dx.doi.org/10.3389/fendo.2017.00006] [PMID: 28167928]
[11]
Peene, B.; Benhalima, K. Sodium glucose transporter protein 2 inhibitors: Focusing on the kidney to treat type 2 diabetes. Ther. Adv. Endocrinol. Metab., 2014, 5(5), 124-136.
[http://dx.doi.org/10.1177/2042018814553965] [PMID: 25419452]
[12]
Heerspink, H.J.L.; Perkins, B.A.; Fitchett, D.H.; Husain, M.; Cherney, D.Z.I. Sodium-glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus. Circulation, 2016, 134(10), 752-772.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.116.021887] [PMID: 27470878]
[13]
Lim, S.; Bae, J.H.; Kwon, H.S.; Nauck, M.A. COVID-19 and diabetes mellitus: From pathophysiology to clinical management. Nat. Rev. Endocrinol., 2021, 17(1), 11-30.
[http://dx.doi.org/10.1038/s41574-020-00435-4] [PMID: 33188364]
[14]
Kalra, S. Sodium-Glucose Co-Transporter-2 (SGLT2) inhibitors: A review of their basic and clinical pharmacology. Diabetes Ther., 2014, 5(2), 355-366.
[http://dx.doi.org/10.1007/s13300-014-0089-4] [PMID: 25424969]
[15]
Tentolouris, A.; Vlachakis, P.; Tzeravini, E.; Eleftheriadou, I.; Tentolouris, N. SGLT2 inhibitors: A review of their antidiabetic and cardioprotective effects. Int. J. Environ. Res. Public Health, 2019, 16(16), 2965.
[http://dx.doi.org/10.3390/ijerph16162965] [PMID: 31426529]
[16]
Chu, C.; Lu, Y.P.; Yin, L.; Hocher, B. The SGLT2 inhibitor empagliflozin might be a new approach to prevent acute kidney injury. Kidney Blood Press. Res., 2019, 44(2), 149-157.
[http://dx.doi.org/10.1159/000498963] [PMID: 30939483]
[17]
Xu, D.; Chandler, O.; Wee, C.; Ho, C.; Affandi, J.S.; Yang, D.; Liao, X.; Chen, W.; Li, Y.; Reid, C.; Xiao, H. Sodium-glucose cotransporter-2 inhibitor (SGLT2i) as a primary preventative agent in the healthy individual: A need of a future randomised clinical trial? Front. Med., 2021, 8712671
[http://dx.doi.org/10.3389/fmed.2021.712671] [PMID: 34497814]
[18]
Lupsa, B.C.; Inzucchi, S.E. Use of SGLT2 inhibitors in type 2 diabetes: Weighing the risks and benefits. Diabetologia, 2018, 61(10), 2118-2125.
[http://dx.doi.org/10.1007/s00125-018-4663-6] [PMID: 30132031]
[19]
Cai, R.; Xu, Y.; Su, Q. Dapagliflozin in patients with chronic heart failure: A systematic review and meta-analysis. Cardiol. Res. Pract., 2021, 2021, 1-12.
[http://dx.doi.org/10.1155/2021/6657380] [PMID: 33859839]
[20]
Martinez, F.A.; Serenelli, M.; Nicolau, J.C.; Petrie, M.C.; Chiang, C.E.; Tereshchenko, S.; Solomon, S.D.; Inzucchi, S.E.; Køber, L.; Kosiborod, M.N.; Ponikowski, P.; Sabatine, M.S.; DeMets, D.L.; Dutkiewicz-Piasecka, M.; Bengtsson, O.; Sjöstrand, M.; Langkilde, A.M.; Jhund, P.S.; McMurray, J.J.V. Efficacy and safety of dapagliflozin in heart failure with reduced ejection fraction according to age. Circulation, 2020, 141(2), 100-111.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.119.044133] [PMID: 31736328]
[21]
Vasquez-Rios, G.; Nadkarni, G.N. SGLT2 inhibitors: Emerging roles in the protection against cardiovascular and kidney disease among diabetic patients. Int. J. Nephrol. Renovasc. Dis., 2020, 13, 281-296.
[http://dx.doi.org/10.2147/IJNRD.S268811] [PMID: 33149657]
[22]
Giorgino, F.; Vora, J.; Fenici, P.; Solini, A. Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal risk. Cardiovasc. Diabetol., 2020, 19(1), 196.
[http://dx.doi.org/10.1186/s12933-020-01163-9] [PMID: 33222693]
[23]
Kuriyama, S. A potential mechanism of cardio-renal protection with sodium-glucose cotransporter 2 inhibitors: Amelioration of renal congestion. Kidney Blood Press. Res., 2019, 44(4), 449-456.
[http://dx.doi.org/10.1159/000501081] [PMID: 31291624]
[24]
Uthman, L.; Baartscheer, A.; Schumacher, C.A.; Fiolet, J.W.T.; Kuschma, M.C.; Hollmann, M.W.; Coronel, R.; Weber, N.C.; Zuurbier, C.J. Direct cardiac actions of sodium-glucose cotransporter 2 inhibitors target pathogenic mechanisms underlying heart failure in diabetic patients. Front. Physiol., 2018, 9, 1575.
[http://dx.doi.org/10.3389/fphys.2018.01575] [PMID: 30519189]
[25]
Joshi, S.S.; Singh, T.; Newby, D.E.; Singh, J. Sodium-glucose co-transporter 2 inhibitor therapy: Mechanisms of action in heart failure. Heart, 2021, 107(13), 1032-1038.
[http://dx.doi.org/10.1136/heartjnl-2020-318060]
[26]
Verma, S. Potential mechanisms of sodium-glucose co-transporter 2 inhibitor-related cardiovascular benefits. Am. J. Cardiol., 2019, 124(10)(Suppl. 1), S36-S44.
[http://dx.doi.org/10.1016/j.amjcard.2019.10.028] [PMID: 31741439]
[27]
Neuen, B.L.; Young, T.; Heerspink, H.J.L.; Neal, B.; Perkovic, V.; Billot, L.; Mahaffey, K.W.; Charytan, D.M.; Wheeler, D.C.; Arnott, C.; Bompoint, S.; Levin, A.; Jardine, M.J. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: A systematic review and meta-analysis. Lancet Diabetes Endocrinol., 2019, 7(11), 845-854.
[http://dx.doi.org/10.1016/S2213-8587(19)30256-6] [PMID: 31495651]
[28]
Davidson, J.A. SGLT2 inhibitors in patients with type 2 diabetes and renal disease: Overview of current evidence. Postgrad. Med., 2019, 131(4), 251-260.
[http://dx.doi.org/10.1080/00325481.2019.1601404] [PMID: 30929540]
[29]
Arnott, C.; Li, Q.; Kang, A.; Neuen, B.L.; Bompoint, S.; Lam, C.S.P.; Rodgers, A.; Mahaffey, K.W.; Cannon, C.P.; Perkovic, V.; Jardine, M.J.; Neal, B. Sodium‐glucose cotransporter 2 inhibition for the prevention of cardiovascular events in patients with type 2 diabetes mellitus: A systematic review and meta‐analysis. J. Am. Heart Assoc., 2020, 9(3)e014908
[http://dx.doi.org/10.1161/JAHA.119.014908] [PMID: 31992158]
[30]
Milder, T.Y.; Stocker, S.L.; Day, R.O.; Greenfield, J.R. Potential safety issues with use of sodium-glucose cotransporter 2 inhibitors, particularly in people with type 2 diabetes and chronic kidney disease. Drug Saf., 2020, 43(12), 1211-1221.
[http://dx.doi.org/10.1007/s40264-020-01010-6] [PMID: 33095409]
[31]
Morris, D. SGLT2 inhibitors – Moving on with the evidence. J. Diabetes Nurs., 2019, 23(4)
[32]
Gyimesi, G.; Pujol-Giménez, J.; Kanai, Y.; Hediger, M.A. Sodium-coupled glucose transport, the SLC5 family, and therapeutically relevant inhibitors: From molecular discovery to clinical application. Pflugers Arch., 2020, 472(9), 1177-1206.
[http://dx.doi.org/10.1007/s00424-020-02433-x] [PMID: 32767111]
[33]
Sano, R.; Shinozaki, Y.; Ohta, T. Sodium–glucose cotransporters: Functional properties and pharmaceutical potential. J. Diabetes Investig., 2020, 11(4), 770-782.
[http://dx.doi.org/10.1111/jdi.13255] [PMID: 32196987]
[34]
Santer, R.; Calado, J. Familial renal glucosuria and SGLT2: From a mendelian trait to a therapeutic target. Clin. J. Am. Soc. Nephrol., 2010, 5(1), 133-141.
[http://dx.doi.org/10.2215/CJN.04010609] [PMID: 19965550]
[35]
Pérez López, G.; González Albarrán, O.; Cano Megías, M. Sodium-glucose cotransporter type 2 inhibitors (SGLT2): From familial renal glucosuria to the treatment of type 2 diabetes mellitus. Nefrologia, 2010, 30(6), 618-625.
[PMID: 21113210]
[36]
Sahoo, S.; Aurich, M.K.; Jonsson, J.J.; Thiele, I. Membrane transporters in a human genome-scale metabolic knowledgebase and their implications for disease. Front. Physiol., 2014, 5, 91.
[http://dx.doi.org/10.3389/fphys.2014.00091] [PMID: 24653705]
[37]
Ni, L.; Yuan, C.; Chen, G.; Zhang, C.; Wu, X. SGLT2i: Beyond the glucose-lowering effect. Cardiovasc. Diabetol., 2020, 19(1), 98.
[http://dx.doi.org/10.1186/s12933-020-01071-y] [PMID: 32590982]
[38]
Abdul-Ghani, M.A.; Norton, L.; DeFronzo, R.A. Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus. Am. J. Physiol. Renal Physiol., 2015, 309(11), F889-F900.
[http://dx.doi.org/10.1152/ajprenal.00267.2015] [PMID: 26354881]
[39]
Ghezzi, C.; Loo, D.D.F.; Wright, E.M. Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2. Diabetologia, 2018, 61(10), 2087-2097.
[http://dx.doi.org/10.1007/s00125-018-4656-5] [PMID: 30132032]
[40]
Ferrannini, E. Sodium-glucose co-transporters and their inhibition: Clinical physiology. Cell Metab., 2017, 26(1), 27-38.
[http://dx.doi.org/10.1016/j.cmet.2017.04.011] [PMID: 28506519]
[41]
Singh, P.; Jain, P.; Shukla, S.; Pandey, R. Phytotherapeutic review on diabetes. Spat DD – Peer. Rev. J. Complement. Med. Drug Discov., 2016, 6(2), 1.
[42]
Harada, N.; Inagaki, N. Role of sodium-glucose transporters in glucose uptake of the intestine and kidney. J. Diabetes Investig., 2012, 3(4), 352-353.
[http://dx.doi.org/10.1111/j.2040-1124.2012.00227.x] [PMID: 24843589]
[43]
Chen, J.; Williams, S.; Ho, S.; Loraine, H.; Hagan, D.; Whaley, J.M.; Feder, J.N. Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members. Diabetes Ther., 2010, 1(2), 57-92.
[http://dx.doi.org/10.1007/s13300-010-0006-4] [PMID: 22127746]
[44]
Szablewski, L. Distribution of glucose transporters in renal diseases. J. Biomed. Sci., 2017, 24(1), 64.
[http://dx.doi.org/10.1186/s12929-017-0371-7] [PMID: 28854935]
[45]
Augustin, R. Mammalian sugar transporters. In: Glucose Homeostasis; Szablewski, E.M.E.L., Ed.; IntechOpen: Rijeka, 2014.
[http://dx.doi.org/10.5772/58325]
[46]
Lam, C.S.P.; Chandramouli, C.; Ahooja, V.; Verma, S. SGLT‐2 inhibitors in heart failure: Current management, unmet needs, and therapeutic prospects. J. Am. Heart Assoc., 2019, 8(20)e013389
[http://dx.doi.org/10.1161/JAHA.119.013389] [PMID: 31607208]
[47]
Griffin, M.; Rao, V.S.; Ivey-Miranda, J.; Fleming, J.; Mahoney, D.; Maulion, C.; Suda, N.; Siwakoti, K.; Ahmad, T.; Jacoby, D.; Riello, R.; Bellumkonda, L.; Cox, Z.; Collins, S.; Jeon, S.; Turner, J.M.; Wilson, F.P.; Butler, J.; Inzucchi, S.E.; Testani, J.M. Empagliflozin in heart failure. Circulation, 2020, 142(11), 1028-1039.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.120.045691] [PMID: 32410463]
[48]
Packer, M.; Anker, S.D.; Butler, J.; Filippatos, G.; Pocock, S.J.; Carson, P.; Januzzi, J.; Verma, S.; Tsutsui, H.; Brueckmann, M.; Jamal, W.; Kimura, K.; Schnee, J.; Zeller, C.; Cotton, D.; Bocchi, E.; Böhm, M.; Choi, D.J.; Chopra, V.; Chuquiure, E.; Giannetti, N.; Janssens, S.; Zhang, J.; Gonzalez Juanatey, J.R.; Kaul, S.; Brunner-La Rocca, H.P.; Merkely, B.; Nicholls, S.J.; Perrone, S.; Pina, I.; Ponikowski, P.; Sattar, N.; Senni, M.; Seronde, M.F.; Spinar, J.; Squire, I.; Taddei, S.; Wanner, C.; Zannad, F. Cardiovascular and renal outcomes with empagliflozin in heart failure. N. Engl. J. Med., 2020, 383(15), 1413-1424.
[http://dx.doi.org/10.1056/NEJMoa2022190] [PMID: 32865377]
[49]
Shao, Q.; Meng, L.; Lee, S.; Tse, G.; Gong, M.; Zhang, Z.; Zhao, J.; Zhao, Y.; Li, G.; Liu, T. Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet/streptozotocin-induced diabetic rats. Cardiovasc. Diabetol., 2019, 18(1), 165.
[http://dx.doi.org/10.1186/s12933-019-0964-4] [PMID: 31779619]
[50]
Das, U.S.; Paul, A.; Banerjee, S. SGLT2 inhibitors in heart failure with reduced ejection fraction. Egypt. Heart J., 2021, 73(1), 93.
[http://dx.doi.org/10.1186/s43044-021-00218-w] [PMID: 34693498]
[51]
Zinman, B.; Wanner, C.; Lachin, J.M.; Fitchett, D.; Bluhmki, E.; Hantel, S.; Mattheus, M.; Devins, T.; Johansen, O.E.; Woerle, H.J.; Broedl, U.C.; Inzucchi, S.E. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med., 2015, 373(22), 2117-2128.
[http://dx.doi.org/10.1056/NEJMoa1504720] [PMID: 26378978]
[52]
Budoff, M.J.; Wilding, J.P.H. Effects of canagliflozin on cardiovascular risk factors in patients with type 2 diabetes mellitus. Int. J. Clin. Pract., 2017, 71(5)e12948
[http://dx.doi.org/10.1111/ijcp.12948] [PMID: 28508457]
[53]
Schernthaner, G.; Shehadeh, N.; Ametov, A.S.; Bazarova, A.V.; Ebrahimi, F.; Fasching, P.; Janež, A.; Kempler, P. Konrāde, I.; Lalić N.M.; Mankovsky, B.; Martinka, E.; Rahelić D.; Serafinceanu, C.; Škrha, J.; Tankova, T.; Visockienė Ž. Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes. Cardiovasc. Diabetol., 2020, 19(1), 185.
[PMID: 33097060]
[54]
Rangaswami, J.; Bhalla, V.; de Boer, I.H.; Staruschenko, A.; Sharp, J.A.; Singh, R.R.; Lo, K.B.; Tuttle, K.; Vaduganathan, M.; Ventura, H.; McCullough, P.A. Cardiorenal protection with the newer antidiabetic agents in patients with diabetes and chronic kidney disease: A scientific statement from the American heart association. Circulation, 2020, 142(17), e265-e286.
[http://dx.doi.org/10.1161/CIR.0000000000000920] [PMID: 32981345]
[55]
Saleem, F. Dapagliflozin: Cardiovascular safety and benefits in type 2 diabetes mellitus. Cureus, 2017, 9(10)e1751
[http://dx.doi.org/10.7759/cureus.1751] [PMID: 29226041]
[56]
Wiviott, S.D.; Raz, I.; Bonaca, M.P.; Mosenzon, O.; Kato, E.T.; Cahn, A.; Silverman, M.G.; Zelniker, T.A.; Kuder, J.F.; Murphy, S.A.; Bhatt, D.L.; Leiter, L.A.; McGuire, D.K.; Wilding, J.P.H.; Ruff, C.T.; Gause-Nilsson, I.A.M.; Fredriksson, M.; Johansson, P.A.; Langkilde, A.M.; Sabatine, M.S. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med., 2019, 380(4), 347-357.
[http://dx.doi.org/10.1056/NEJMoa1812389] [PMID: 30415602]
[57]
Zhai, M.; Du, X.; Liu, C.; Xu, H. The effects of dapagliflozin in patients with heart failure complicated with type 2 diabetes: a meta-analysis of placebo-controlled randomized trials. Front. Clin. Diabetes Healthc., 2021, 2703937
[58]
Neeland, I.J.; Salahuddin, U.; McGuire, D.K. A safety evaluation of empagliflozin for the treatment of type 2 diabetes. Expert Opin. Drug Saf., 2016, 15(3), 393-402.
[http://dx.doi.org/10.1517/14740338.2016.1135900] [PMID: 26695551]
[59]
Jain, A.; Jain, P.; Parihar, D.K. Comparative study of in-vitro antidiabetic and antibacterial activity of non-conventional curcuma species. J. Biologic. Active Prod. Nature, 2019, 9(6), 457-464.
[http://dx.doi.org/10.1080/22311866.2019.1710253]
[60]
Ferdinand, K.C.; Izzo, J.L.; Lee, J.; Meng, L.; George, J.; Salsali, A.; Seman, L. Antihyperglycemic and blood pressure effects of empagliflozin in black patients with type 2 diabetes mellitus and hypertension. Circulation, 2019, 139(18), 2098-2109.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.118.036568] [PMID: 30786754]
[61]
Marrs, J.C.; Anderson, S.L. Ertugliflozin in the treatment of type 2 diabetes mellitus. Drugs Context, 2020, 9, 1-10.
[http://dx.doi.org/10.7573/dic.2020-7-4] [PMID: 33293984]
[62]
Zhang, C.; Zhang, X.; Wang, P.; Zhu, Q.; Mei, Y.; Zhang, Z.; Xu, H. Effect of SGLT2 inhibitors on risk of stroke in diabetes: A meta-analysis. Cerebrovasc. Dis., 2022, 51(5), 585-593.
[http://dx.doi.org/10.1159/000521782] [PMID: 35100586]
[63]
Cowie, M.R.; Fisher, M. SGLT2 inhibitors: Mechanisms of cardiovascular benefit beyond glycaemic control. Nat. Rev. Cardiol., 2020, 17(12), 761-772.
[http://dx.doi.org/10.1038/s41569-020-0406-8] [PMID: 32665641]
[64]
Lopaschuk, G.D.; Verma, S. Mechanisms of cardiovascular benefits of sodium-glucose co-transporter 2 (SGLT2) inhibitors: A state-of-the-art review. JACC Basic Transl. Sci., 2020, 5(6), 632-644.
[http://dx.doi.org/10.1016/j.jacbts.2020.02.004] [PMID: 32613148]
[65]
Wilkinson, I.B.; McEniery, C.M. Arterial stiffness, endothelial function and novel pharmacological approaches. Clin. Exp. Pharmacol. Physiol., 2004, 31(11), 795-799.
[http://dx.doi.org/10.1111/j.1440-1681.2004.04074.x] [PMID: 15566396]
[66]
Cherney, D.Z.I.; Perkins, B.A.; Soleymanlou, N.; Har, R.; Fagan, N.; Johansen, O.; Woerle, H.J.; von Eynatten, M.; Broedl, U.C. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc. Diabetol., 2014, 13(1), 28.
[http://dx.doi.org/10.1186/1475-2840-13-28] [PMID: 24475922]
[67]
Lee, T.M.; Chang, N.C.; Lin, S.Z. Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts. Free Radic. Biol. Med., 2017, 104, 298-310.
[http://dx.doi.org/10.1016/j.freeradbiomed.2017.01.035] [PMID: 28132924]
[68]
Thrailkill, K.M.; Bunn, R.C.; Uppuganti, S.; Ray, P.; Garrett, K.; Popescu, I.; Pennings, J.S.; Fowlkes, J.L.; Nyman, J.S. Genetic ablation of SGLT2 function in mice impairs tissue mineral density but does not affect fracture resistance of bone. Bone, 2020, 133115254
[http://dx.doi.org/10.1016/j.bone.2020.115254] [PMID: 31991250]
[69]
McMurray, J.J.V.; Solomon, S.D.; Inzucchi, S.E.; Køber, L.; Kosiborod, M.N.; Martinez, F.A.; Ponikowski, P.; Sabatine, M.S.; Anand, I.S. Bělohlávek, J.; Böhm, M.; Chiang, C.E.; Chopra, V.K.; de Boer, R.A.; Desai, A.S.; Diez, M.; Drozdz, J.; Dukát, A.; Ge, J.; Howlett, J.G.; Katova, T.; Kitakaze, M.; Ljungman, C.E.A.; Merkely, B.; Nicolau, J.C.; O’Meara, E.; Petrie, M.C.; Vinh, P.N.; Schou, M.; Tereshchenko, S.; Verma, S.; Held, C.; DeMets, D.L.; Docherty, K.F.; Jhund, P.S.; Bengtsson, O.; Sjöstrand, M.; Langkilde, A.M. Dapagliflozin in patients with heart failure and reduced ejection fraction. N. Engl. J. Med., 2019, 381(21), 1995-2008.
[http://dx.doi.org/10.1056/NEJMoa1911303] [PMID: 31535829]
[70]
Mendoza, V.L.; Tumanan-Mendoza, B.A.; Punzalan, F.E.R. Cost‐utility analysis of add‐on dapagliflozin in heart failure with reduced ejection fraction in the Philippines. ESC Heart Fail., 2021, 8(6), 5132-5141.
[http://dx.doi.org/10.1002/ehf2.13583] [PMID: 34494399]
[71]
Hayashi, T.; Fukui, T.; Nakanishi, N.; Yamamoto, S.; Tomoyasu, M.; Osamura, A.; Ohara, M.; Yamamoto, T.; Ito, Y.; Hirano, T. Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: Comparison with sitagliptin. Cardiovasc. Diabetol., 2017, 16(1), 8.
[http://dx.doi.org/10.1186/s12933-016-0491-5] [PMID: 28086872]
[72]
Pittampalli, S.; Upadyayula, S.; Mekala, H.M.; Lippmann, S. Risks vs benefits for SGLT2 inhibitor medications. Fed. Pract., 2018, 35(7), 45-48.
[PMID: 30766374]
[73]
Kalra, S. Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors and cardiovascular disease: A systematic review. Cardiol. Ther., 2016, 5(2), 161-168.
[http://dx.doi.org/10.1007/s40119-016-0069-z] [PMID: 27539303]
[74]
Vasilakou, D.; Karagiannis, T.; Athanasiadou, E.; Mainou, M.; Liakos, A.; Bekiari, E.; Sarigianni, M.; Matthews, D.R.; Tsapas, A. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: A systematic review and meta-analysis. Ann. Intern. Med., 2013, 159(4), 262-274.
[http://dx.doi.org/10.7326/0003-4819-159-4-201308200-00007] [PMID: 24026259]
[75]
Deedwania, P. SGLT2 inhibitors: The dawn of a new era in cardio-metabolic therapeutics. Am. J. Cardiovasc. Drugs, 2022, 22(1), 1-4.
[http://dx.doi.org/10.1007/s40256-021-00495-5] [PMID: 34458960]
[76]
Packer, M. SGLT2 inhibitors produce cardiorenal benefits by promoting adaptive cellular reprogramming to induce a state of fasting mimicry: A paradigm shift in understanding their mechanism of action. Diabetes Care, 2020, 43(3), 508-511.
[http://dx.doi.org/10.2337/dci19-0074] [PMID: 32079684]
[77]
Scheen, A.J. Effect of SGLT2 inhibitors on the sympathetic nervous system and blood pressure. Curr. Cardiol. Rep., 2019, 21(8), 70.
[http://dx.doi.org/10.1007/s11886-019-1165-1] [PMID: 31227915]
[78]
Grassi, G.; Mark, A.; Esler, M. The sympathetic nervous system alterations in human hypertension. Circ. Res., 2015, 116(6), 976-990.
[http://dx.doi.org/10.1161/CIRCRESAHA.116.303604] [PMID: 25767284]
[79]
Parati, G.; Esler, M. The human sympathetic nervous system: Its relevance in hypertension and heart failure. Eur. Heart J., 2012, 33(9), 1058-1066.
[PMID: 22507981]
[80]
Toschi-Dias, E.; Rondon, M.U.P.B.; Cogliati, C.; Paolocci, N.; Tobaldini, E.; Montano, N. Contribution of autonomic reflexes to the hyperadrenergic state in heart failure. Front. Neurosci., 2017, 11, 162.
[http://dx.doi.org/10.3389/fnins.2017.00162] [PMID: 28424575]
[81]
van Bilsen, M.; Patel, H.C.; Bauersachs, J.; Böhm, M.; Borggrefe, M.; Brutsaert, D.; Coats, A.J.S.; de Boer, R.A.; de Keulenaer, G.W.; Filippatos, G.S.; Floras, J.; Grassi, G.; Jankowska, E.A.; Kornet, L.; Lunde, I.G.; Maack, C.; Mahfoud, F.; Pollesello, P.; Ponikowski, P.; Ruschitzka, F.; Sabbah, H.N.; Schultz, H.D.; Seferovic, P.; Slart, R.H.J.A.; Taggart, P.; Tocchetti, C.G.; Van Laake, L.W.; Zannad, F.; Heymans, S.; Lyon, A.R. The autonomic nervous system as a therapeutic target in heart failure: A scientific position statement from the translational research committee of the heart failure association of the european society of cardiology. Eur. J. Heart Fail., 2017, 19(11), 1361-1378.
[http://dx.doi.org/10.1002/ejhf.921] [PMID: 28949064]
[82]
Briasoulis, A.; Al Dhaybi, O.; Bakris, G.L. SGLT2 inhibitors and mechanisms of hypertension. Curr. Cardiol. Rep., 2018, 20(1), 1.
[http://dx.doi.org/10.1007/s11886-018-0943-5] [PMID: 29349558]
[83]
Donkor, E.S. Stroke in the 21st century: A snapshot of the burden, epidemiology, and quality of life. Stroke Res. Treat., 2018, 2018, 1-10.
[http://dx.doi.org/10.1155/2018/3238165] [PMID: 30598741]
[84]
Shi, L.; Rocha, M.; Leak, R.K.; Zhao, J.; Bhatia, T.N.; Mu, H.; Wei, Z.; Yu, F.; Weiner, S.L.; Ma, F.; Jovin, T.G.; Chen, J. A new era for stroke therapy: Integrating neurovascular protection with optimal reperfusion. J. Cereb. Blood Flow Metab., 2018, 38(12), 2073-2091.
[http://dx.doi.org/10.1177/0271678X18798162] [PMID: 30191760]
[85]
Al Hamed, F.A.; Elewa, H. Potential therapeutic effects of sodium glucose-linked cotransporter 2 inhibitors in stroke. Clin. Ther., 2020, 42(11), e242-e249.
[http://dx.doi.org/10.1016/j.clinthera.2020.09.008] [PMID: 33008610]
[86]
Tsai, W.H.; Chuang, S.M.; Liu, S.C.; Lee, C.C.; Chien, M.N.; Leung, C.H.; Liu, S.J.; Shih, H.M. Effects of SGLT2 inhibitors on stroke and its subtypes in patients with type 2 diabetes: A systematic review and meta-analysis. Sci. Rep., 2021, 11(1), 15364.
[http://dx.doi.org/10.1038/s41598-021-94945-4] [PMID: 34321571]
[87]
Zhou, Z.; Jardine, M.J.; Li, Q.; Neuen, B.L.; Cannon, C.P.; de Zeeuw, D.; Edwards, R.; Levin, A.; Mahaffey, K.W.; Perkovic, V.; Neal, B.; Lindley, R.I.; Ahuad, R.A.; Aizenberg, D.; Albisu, J.P.; Alvarisqueta, A.; Bartolacci, I.; Berli, M.A.; Bordonava, A.; Calella, P.; Cantero, M.C.; Cartasegna, L.R.; Cercos, E.; Coloma, G.C.; Colombo, H.; Commendatore, V.; Cuadrado, J.; Cuneo, C.A.; Cusumano, A.M.; Douthat, W.G.; Dran, R.D.; Farias, E.; Fernandez, M.F.; Finkelstein, H.; Fragale, G.; Fretes, J.O.; Garcia, N.H.; Gastaldi, A.; Gelersztein, E.; Glenny, J.A.; Gonzalez, J.P.; del Carmen Gonzalez Colaso, P.; Goycoa, C.; Greloni, G.C.; Guinsburg, A.; Hermida, S.; Juncos, L.I.; Klyver, M.I.; Kraft, F.; Krynski, F.; Lanchiotti, P.V.; Leon de la Fuente, R.A.; Marchetta, N.; Mele, P.; Nicolai, S.; Novoa, P.A.; Orio, S.I.; Otreras, F.; Oviedo, A.; Raffaele, P.; Resk, J.H.; Rista, L.; Rodriguez, N.; Sala, J.; Santos, J.C.; Schiavi, L.B.; Sessa, H.; Smith Casabella, T.; Ulla, M.R.; Valdez, M.; Vallejos, A.; Villarino, A.; Visco, V.E.; Wassermann, A.; Zaidman, C.J.; Cheung, N.W.; Droste, C.; Fraser, I.; Johnson, D.; Mah, P.M.; Nicholls, K.; Packham, D.; Proietto, J.; Roberts, A.; Roger, S.; Tsang, V.; Abrão, R. R.; Alves da Costa, F.A.; Amodeo, C.; Andreotti T., L.A.; Bregman, R.; Camelo Sanches, F.C.; Canani, L.H.; Chacra, A.R.; Cunha Borges, J.L.; Cunha Vêncio, S.A.; da Silva Franco, R.J.; d’Avila, D.; de Souza Portes, E.; de Souza, P.; Deboni, L.M.; Fraige Filho, F.; Geloneze Neto, B.; Gomes, M.; Keiko, K., S.; Keitel, E.; Kerr Saraiva, J.F.; Kurtz, L., H.R.; Loss de Carvalho Contieri, F.; Milagres, R.; Montenegro J., R.; Moreira de Brito, C.; Nasser, H. M.; Nazario, S., Â.R.; Noronha, I.; Panarotto, D.; Pecoits, F., R.; Pereira, M.A.; Saporito, W.; Scafuto S., A.; Schuch, T.; Simões de Almeida, R.; Slompo R, C.; Soares Felício, J.; Thomé, F.; Tibes Hachmann, J.C.; Yamada, S.; Yoiti H., C.; Zanata P., T.B.; Zanella, M.T.; Andreeva, V.; Angelova, A.; Dimitrov, S.; Genadieva, V.; Genova-Hristova, G.; Hristozov, K.; Kamenov, Z.; Koundurdjiev, A.; Lozanov, L.; Margaritov, V.; Nonchev, B.; Rangelov, R.; Shinkov, A.; Temelkova, M.; Velichkova, E.; Yakov, A.; Aggarwal, N.; Aronson, R.; Bajaj, H.; Cherney, D.; Chouinard, G.; Conway, J.; Cournoyer, S.; DaRoza, G.; De Serres, S.; Dubé, F.; Goldenberg, R.; Gupta, A.; Gupta, M.; Henein, S.; Khandwala, H.; Leiter, L.; Madore, F.; McMahon, A.; Muirhead, N.; Pichette, V.; Rabasa-Lhoret, R.; Steele, A.; Tangri, N.; Torshizi, A.; Woo, V.; Zalunardo, N.; Fernández, M., M.A.; Godoy J., J.G.; Medina, F., M.; Saavedra Gajardo, V.; Vejar, M.; Chen, N.; Chen, Q.; Gan, S.; Kong, Y.; Li, D.; Li, W.; Li, X.; Lin, H.; Liu, J.; Lu, W.; Mao, H.; Ren, Y.; Song, W.; Sun, J.; Sun, L.; Tu, P.; Wang, G.; Yang, J.; Yin, A.; Yu, X.; Zhao, M.; Zheng, H.; Accini, M., J.L.; Arcos, E.; Avendano, J.; Diaz Ruiz, J.E.A.; Garcia Ortiz, L.H.; Gonzalez, A.; Hernandez, T., E.; Higuera, J.D.; Malaver, N.; Molina de Salazar, D.I.; Rosero, R.; Terront, L., M.A.; Valderrama, C., L.; Valenzuela, A.; Vargas Alonso, R.D.; Villegas, I.; Yupanqui, H.; Bartaskova, D.; Barton, P.; Belobradkova, J.; Dohnalova, L.; Drasnar, T.; Ferkl, R.; Halciakova, K.; Klokocnikova, V.; Kovar, R.; Lastuvka, J.; Lukac, M.; Pesickova, S.; Peterka, K.; Pumprla, J.; Rychlik, I.; Saudek, F.; Tesar, V.; Valis, M.; Weiner, P.; Zemek, S.; Alamartine, E.; Borot, S.; Cariou, B.; Dussol, B.; Fauvel, J-P.; Gourdy, P.; Klein, A.; Le Meur, Y.; Penfornis, A.; Roussel, R.; Saulnier, P-J.; Thervet, E.; Zaoui, P.; Burst, V.; Faghih, M.; Faulmann, G.; Haller, H.; Jerwan-Keim, R.; Maxeiner, S.; Paschen, B.; Plassmann, G.; Rose, L.; Gonzalez Orellana, R.A.; Haase, F.P.; Moreira Diaz, J.P.; Ramirez Roca, L.A.; Sánchez Arenales, J.A.; Sanchez Polo, J.V.; Turcios Juarez, E.; Csecsei, G.; Csiky, B.; Danos, P.; Deak, L.; Dudas, M.; Harcsa, E.; Keltai, K.; Keresztesi, S.; Kiss, K.; Konyves, L.; Major, L.; Mileder, M.; Molnar, M.; Mucsi, J.; Oroszlan, T.; Ory, I.; Paragh, G.; Peterfai, E.; Petro, G.; Revesz, K.; Takacs, R.; Vangel, S.; Vasas, S.; Zsom, M.; Oomman, A.; Raju, S.B.; Dewan, D.; Fernando, M.E.; Gopalakrishnan, N.; Gracious, N.; Alva, H.; Jain, D.; Keshavamurthy, C.B.; Khullar, D.; Sahay, M.; Peringat, J.; Prasad, N.; Rao, K.S.; Reddy, S.; Melemadathil, S.; Sudhakar, B.; Vyasam, R.C.; Bonadonna, R.; Castellino, P.; Ceriello, A.; Chiovato, L.; De Cosmo, S.; De Nicola, L.; Derosa, G.; Di Carlo, A.; Di Cianni, G.; Frascà, G.; Fuiano, G.; Gambaro, G.; Garibotto, G.; Giorda, C.; Malberti, F.; Mandreoli, M.; Mannucci, E.; Orsi, E.; Piatti, P.; Santoro, D.; Sasso, F.C.; Serviddio, G.; Stella, A.; Trevisan, R.; Veronelli, A.M.; Zanoli, L.; Akiyama, H.; Aoki, H.; Asano, A.; Iitsuka, T.; Kajiyama, S.; Kashine, S.; Kawada, T.; Kodera, T.; Kono, H.; Koyama, K.; Kumeda, Y.; Miyauchi, S.; Mizuyama, K.; Niiya, T.; Oishi, H.; Ota, S.; Sakakibara, T.; Takai, M.; Tomonaga, O.; Tsujimoto, M.; Wada, T.; Wakasugi, M.; Wakida, Y.; Watanabe, T.; Yamada, M.; Yanagida, K.; Yanase, T.; Yumita, W.; Gaupsiene, E.; Kozloviene, D.; Navickas, A.; Urbanaviciene, E.; Abdul Ghani, R.; Abdul K., K.; Ali, N.; Che Y., M.D.; Gan, C.L.; Ismail, M.; Kong, W.Y.; Lam, S.W.; Lee, L.Y.; Lim, S.K.; Loh, C.L.; Manocha, A.B.; Ng, K.S.; Nik Ahmad, N.N.F.; Ratnasingam, V.; Shudim, S.S.B.; Vengadasalam, P.; Abraira M., L.D.; Alpizar Salazar, M.; Baas Cruz, J.; Burgos S., M.; Chevaile R., J.; Chew Wong, A.; Correa R., J.R.; Diaz E., T.; Enriquez S., F.E.; Flores L., F.; Flota C., L.F.; Frenk B., P.; Garcia Ballesteros, C.; Gomez R., J.D.; Herrera J., L.E.; Irizar S., S.S.; Jimenez F.F.; Laviada M., H.; Luna Ceballos, R.I.; Martin del C.B., B.; Morales F., G.; Moreno Loza, O.T.; Mustieles R., C.; Obrador V.G.; Orozco Castellanos, R.; Peralta C., J.; Reyes Rosano, M.A.; Rodriguez Pattzi, H.; Rosas G., J.; Rucker J., I.E.; Saavedra Sanchez, S.B.; Sanchez M., J.H.; Serrano S., P.; Tamayo y Orozco, J.A.; Tellez C., E.; Valdes Cepeda, A.; Venegas Carrillo, L.; Villagordoa Mesa, J.; Zamarripa Escobedo, R.; Baker, J.; Noonan, P.; Scott, R.; Walker, R.; Watson, E.; Williams, M.; Young, S.; Abejuela, Z.; Agra, J.; Aquitania, G.; Caringal, C.; Comia, R.S.; Delos Santos, L.; Gomez, O.; Jimeno, C.; Santos, F.; Tan, G.; Tolentino, M.; Yao, C.; Yap, Y.E.; Ygpuara, M.D.L.; Bijata-Bronisz, R.; Hotlos, L.; Januszewicz, A.; Kaczmarek, B.; Kaminska, A.; Lazuka, L.; Madej, A.; Mazur, S.; Mlodawska-Choluj, D.; Nowicki, M.; Orlowska-Kowalik, G.; Popenda, G.; Rewerska, B.; Sowinski, D.; Angelescu, L.M.; Anghel, V.; Avram, R-I.; Busegeanu, M-M.; Cif, A.; Cosma, D.; Crisan, C.; Demian, L.D.; Ferariu, I.E.; Halmagyi, I.; Hancu, N.; Munteanu, M.; Negru, D.; Onaca, A.G.; Petrica, L.; Popa, A.R.; Ranetti, A-E.; Serafinceanu, C.; Toarba, C.; Agafyina, A.; Barbarash, O.; Barysheva, O.; Chizhov, D.; Dobronravov, V.; Dreval, A.; Glinkina, I.; Grineva, E.; Khirmanov, V.; Kolmakova, E.; Koroleva, T.; Kvitkova, L.; Marasaev, V.; Mkrtumyan, A.; Morugova, T.; Nagibovich, G.; Nagibovich, O.; Nedogoda, S.; Osipova, I.; Raskina, T.; Samoylova, Y.; Sazonova, O.; Shamkhalova, M.; Shutemova, E.; Shwartz, Y.; Uriasyev, O.; Vorobyev, S.; Zateyshchikova, A.; Zateyshshikov, D.; Zykova, T.; Antic, S.; Djordjevic, M.; Kendereski, A.; Lalic, K.; Lalic, N.; Popovic-Radinovic, V.; Babikova, J.; Benusova, O.; Buganova, I.; Culak, J.; Dzupina, A.; Dzuponova, J.; Fulop, P.; Ilavska, A.; Martinka, E.; Ochodnicka, Z.; Pella, D.; Smatanova, I.; Ahmed, F.; Badat, A.; Breedt, J.; Distiller, L.; Govender, V.; Govender, R.; Joshi, M.; Jurgens, J.; Latiff, G.; Lombard, L.; Mookadam, M.; Ngcakani, N.; Nortje, H.; Oosthuizen, H.; Pillay-Ramaya, L.; Prozesky, H.; Reddy, J.; Rheeder, P.; Seeber, M.; Chae, D-W.; Cho, Y.M.; Jeong, I-K.; Kim, S.G.; Kim, Y.H.; Kwon, H-S.; Kwon, M.J.; Lee, B-W.; Lee, J.E.; Lee, M-K.; Nam, M-S.; Oh, K-H.; Park, C-Y.; Park, S-H.; Yoon, K.H.; Alvarez Garcia, P.; Asmarats Mercadal, L.; Barrios, C.; Cereto Castro, F.; Cigarran Guldris, S.; Dominguez L., M.; Egido de los Rios, J.; Fernandez F., G.; Galan S., A.; Garcia, I.; Gonzalez Martinez, F.J.; Jodar G., J.E.; Lopez M., M.; Malek Marin, T.; Morales Portillo, C.; Munar Vila, M.A.; Muñoz T., M.; Nieto Iglesias, J.; Pantoja Perez, J.; Perez Vera, M.; Portoles P., J.M.; Quesada Simón, M.A.; Simo C., R.; Soto Gonzalez, A.; Terns Riera, M.; Tinahones Madueno, F.J.; Velo Plaza, M.; Chang, C-T.; Chuang, L-M.; Hsia, T-L.; Hsieh, C-H.; Hwang, S-J.; Lin, C-C.; Lu, Y-C.; Sheu, W.H-H.; Barna, O.; Bilyk, S.D.; Botsyurko, V.; Dudar, I.; Fushtey, I.; Godlevska, O.; Golovchenko, O.; Gyrina, O.; Kazmirchuk, A.; Kolesnyk, M.; Komisarenko, I.; Korzh, O.; Kravchun, N.; Legun, O.; Mankovskyy, B.; Martynyuk, L.; Mostovoy, Y.; Pashkovska, N.; Pererva, L.; Pertseva, T.; Samoylov, O.; Smirnov, I.; Svyshchenko, Y.; Tomashkevych, H.; Topchii, I.; Tryshchuk, N.; Tseluyko, V.; Vizir, V.; Vlasenko, M.; Zlova, T.; Zub, L.; Abusnana, S.; Railey, M.; Abouglila, K.; Ainsworth, P.; Ali, Z.; Arutchelvam, V.; Barnard, M.; Bellary, S.; Davies, E.; Davies, M.; Davies, S.; Dawson, A.; El Kossi, M.; English, P.; Fraser, D.; Gnudi, L.; Gunstone, A.; Hall, T.; Hanif, W.; Jackson, A.; Johnson, A.; Joseph, F.; Krishnan, S.; Kumwenda, M.; MacDougall, I.; Nixon, P.; O’Hare, J.; Philip, S.; Ramtoola, S.; Saxena, M.; Sennik, D.; Simon, G.; Singh, B.; Stephens, J.; Strzelecka, A.; Symonds, R.; Turner, W.; Wahba, M.; Wakeling, J.; Wheeler, D.; Winocour, P.; Abdallah, J.; Abdullah, R.; Abramowitz, M.; Acosta, I.; Aiello, J.; Akright, L.; Akyea-Djamson, A.; Alappan, R.; Alicic, R.; Al-Karadsheh, A.; Allison, D.C.; Arauz-Pacheco, C.; Arfeen, S.; Arif, A.; Arvind, M.; Atray, N.; Awad, A.; Bakris, G.; Barnhill, P.; Barranco, E.; Barrera, C.; Beacom, M.; Behara, V.; Belo, D.; Bentley-Lewis, R.; Berenguer, R.; Bermudez, L.; Bernardo, M.; Biscoveanu, M.; Bowman-Stroud, C.; Brandon, D.; Brusco, O.; Busch, R.; Canaan, Y.; Chilito, A.; Christensen, T.; Christiano, C.; Christofides, E.; Chuateco, C.; Cohen, K.; Cohen, R.; Cohen-Stein, D.; Cook, C.; Coyne, D.; Daboul, N.; Darwish, R.; Daswani, A.; Deck, K.; Desouza, C.; Dev, D.; Dhillon, M.; Dua, S.; Eder, F.; Elosegui, A.M.; El-Shahawy, M.; Ervin, J.; Esquenazi, A.; Evans, J.; Fishbane, S.; Frias, J.; Galindo-Ramos, E.; Galphin, C.; Ghazi, A.; Gonzalez, E.; Gorson, D.; Gowda, A.; Greco, B.; Grubb, S.; Gulati, R.; Hammoud, J.; Handelsman, S.; Hartman, I.; Hershon, K.; Hiser, D.; Hon, G.; Jacob, R.; Jaime, M.; Jamal, A.; Kaupke, C.; Keightley, G.; Kern, E.; Khanna, R.; Khitan, Z.; Kim, S.; Kopyt, N.; Kovesdy, C.; Krishna, G.; Kropp, J.J.; Kumar, A.; Kumar, J.; Kumar, N.; Kusnir, J.; Lane, W.; Lawrence, M.; Lehrner, L.; Lentz, J.; Levinson, D.; Lewis, D.; Liss, K.; Maddux, A.; Maheshwari, H.; Mandayam, S.; Marar, I.; Mehta, B.; Middleton, J.; Mordujovich, J.; Moreda, R.; Moustafa, M.; Mujica Trenche, S.; Narayanan, M.; Narvarte, J.; Nassar, T.; Newman, G.; Nichol, B.; Nicol, P.; Nisnisan, J.; Nossuli, A.K.; Obialo, C.; Olelewe, S.; Oliver, M.; O’Shaughnessy, A.; Padron, J.; Pankhaniya, R.; Parker, R.; Patel, D.; Patel, G.; Patel, N.; Pavon, H.; Perez, A.; Perez, C.; Perlman, A.; Pettis, K.; Pharr, W.; Phillips, A.; Purighalla, R.; Quesada-Suarez, L.; Ranjan, R.; Rastogi, S.; Reddy, J.; Rendell, M.; Rich, L.; Robinson, M.; Rodriguez, H.; Rosas, S.; Saba, F.; Sankaram, R.; Sarin, R.; Schreiman, R.; Scott, D.; Sekkarie, M.; Sensenbrenner, J.; Shakeel, M.; Shanik, M.; Shaw, S.; Smith, S.; Solomon, R.; Sprague, A.; Spry, L.; Suchinda, P.; Sultan, S.; Surampudi, P.; Sussman, S.; Tan, A.; Terrelonge, A.; Thompson, M.; Trespalacios, F.; Trippe, B.; Trueba, P.; Twahirwa, M.; Updegrove, J.; Van Buren, P.; Vannorsdall, M.; Varghese, F.; Velasquez-Mieyer, P.; Ventrapragada, S.; Vukotic, G.; Wadud, K.; Warren, M.; Watson, H.; Watts, R.; Weiner, D.; Welker, J.; Welsh, J.; Williams, S.; Zaniewski-Singh, M. Effect of SGLT2 inhibitors on stroke and atrial fibrillation in diabetic kidney disease. Stroke, 2021, 52(5), 1545-1556.
[http://dx.doi.org/10.1161/STROKEAHA.120.031623] [PMID: 33874750]
[88]
Dave, C.V.; Kim, S.C.; Goldfine, A.B.; Glynn, R.J.; Tong, A.; Patorno, E. Risk of cardiovascular outcomes in patients with type 2 diabetes after addition of SGLT2 inhibitors versus sulfonylureas to baseline GLP-1RA therapy. Circulation, 2021, 143(8), 770-779.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.120.047965] [PMID: 33302723]
[89]
Ong, H.T.; Teo, Y.H.; Teo, Y.N.; Syn, N.L.X.; Wee, C.F.; Leong, S.; Yip, A.S.Y.; See, R.M.; Ting, A.Z.H.; Chia, A.Z.Q.; Cheong, A.J.Y.; Tan, B.Y.Q.; Ho, J.S.Y.; Yeo, L.L.L.; Leow, A.S.T.; Yeo, T.C.; Wong, R.C.C.; Chai, P.; Kojodjojo, P.; Sia, C.H. Effects of sodium/glucose cotransporter inhibitors on atrial fibrillation and stroke: A meta-analysis. J. Stroke Cerebrovasc. Dis., 2022, 31(1)106159
[http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2021.106159] [PMID: 34689051]
[90]
Guo, M.; Ding, J.; Li, J.; Wang, J.; Zhang, T.; Liu, C.; Huang, W.; Long, Y.; Gao, C.; Xu, Y. SGLT2 inhibitors and risk of stroke in patients with type 2 diabetes: A systematic review and meta-analysis. Diabetes Obes. Metab., 2018, 20(8), 1977-1982.
[http://dx.doi.org/10.1111/dom.13295] [PMID: 29573118]
[91]
Fitchett, D.; Inzucchi, S.E.; Cannon, C.P.; McGuire, D.K.; Scirica, B.M.; Johansen, O.E.; Sambevski, S.; Kaspers, S.; Pfarr, E.; George, J.T.; Zinman, B. Empagliflozin reduced mortality and hospitalization for heart failure across the spectrum of cardiovascular risk in the EMPA-REG outcome trial. Circulation, 2019, 139(11), 1384-1395.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.118.037778] [PMID: 30586757]
[92]
Zannad, F.; Ferreira, J.P.; Pocock, S.J.; Anker, S.D.; Butler, J.; Filippatos, G.; Brueckmann, M.; Ofstad, A.P.; Pfarr, E.; Jamal, W.; Packer, M. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: A meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet, 2020, 396(10254), 819-829.
[http://dx.doi.org/10.1016/S0140-6736(20)31824-9] [PMID: 32877652]
[93]
Packer, M.; Anker, S.D.; Butler, J.; Filippatos, G.; Ferreira, J.P.; Pocock, S.J.; Sattar, N.; Brueckmann, M.; Jamal, W.; Cotton, D.; Iwata, T.; Zannad, F. Empagliflozin in patients with heart failure, reduced ejection fraction, and volume overload: EMPEROR-Reduced trial. J. Am. Coll. Cardiol., 2021, 77(11), 1381-1392.
[http://dx.doi.org/10.1016/j.jacc.2021.01.033] [PMID: 33736819]
[94]
Anker, S.D.; Butler, J.; Filippatos, G.; Ferreira, J.P.; Bocchi, E.; Böhm, M.; Brunner-La Rocca, H.P.; Choi, D.J.; Chopra, V.; Chuquiure-Valenzuela, E.; Giannetti, N.; Gomez-Mesa, J.E.; Janssens, S.; Januzzi, J.L.; Gonzalez-Juanatey, J.R.; Merkely, B.; Nicholls, S.J.; Perrone, S.V.; Piña, I.L.; Ponikowski, P.; Senni, M.; Sim, D.; Spinar, J.; Squire, I.; Taddei, S.; Tsutsui, H.; Verma, S.; Vinereanu, D.; Zhang, J.; Carson, P.; Lam, C.S.P.; Marx, N.; Zeller, C.; Sattar, N.; Jamal, W.; Schnaidt, S.; Schnee, J.M.; Brueckmann, M.; Pocock, S.J.; Zannad, F.; Packer, M. Empagliflozin in heart failure with a preserved ejection fraction. N. Engl. J. Med., 2021, 385(16), 1451-1461.
[http://dx.doi.org/10.1056/NEJMoa2107038] [PMID: 34449189]
[95]
Ptaszynska, A.; Cohen, S.M.; Messing, E.M.; Reilly, T.P.; Johnsson, E.; Johnsson, K. Assessing bladder cancer risk in type 2 diabetes clinical trials: The dapagliflozin drug development program as a “case study.”. Diabetes Ther., 2015, 6(3), 357-375.
[http://dx.doi.org/10.1007/s13300-015-0128-9] [PMID: 26323372]
[96]
Gallwitz, B. Clinical use of DPP-4 inhibitors. Front. Endocrinol., 2019, 10, 389.
[http://dx.doi.org/10.3389/fendo.2019.00389] [PMID: 31275246]
[97]
Unnikrishnan, A.G.; Kalra, S.; Purandare, V.; Vasnawala, H. Genital infections with sodium glucose cotransporter-2 inhibitors: Occurrence and management in patients with type 2 diabetes mellitus. Indian J. Endocrinol. Metab., 2018, 22(6), 837-842.
[http://dx.doi.org/10.4103/ijem.IJEM_159_17] [PMID: 30766827]
[98]
Hu, Y.; Bai, Z.; Tang, Y.; Liu, R.; Zhao, B.; Gong, J. Fournier gangrene associated with sodium-glucose cotransporter-2 inhibitors: A pharmacovigilance study with data from the U.S. FDA adverse event reporting system. J. Diabetes Res., 2020, •••3695101
[99]
Kluger, A.Y.; Tecson, K.M.; Lee, A.Y.; Lerma, E.V.; Rangaswami, J.; Lepor, N.E.; Cobble, M.E.; McCullough, P.A. Class effects of SGLT2 inhibitors on cardiorenal outcomes. Cardiovasc. Diabetol., 2019, 18(1), 99.
[http://dx.doi.org/10.1186/s12933-019-0903-4] [PMID: 31382965]